RNA vaccines: The dawn of a new age for tuberculosis?
Since 2019, there has been a growing focus on mRNA vaccines for infectious disease prevention, particularly following the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). mRNA vaccines offer advantages such as rapid production and the ability to induce robust cellular and a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2469333 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849326075652341760 |
|---|---|
| author | Junli Li Dong Liu Xiaochi Li Jiazheng Wei Weixin Du Aihua Zhao Miao Xu |
| author_facet | Junli Li Dong Liu Xiaochi Li Jiazheng Wei Weixin Du Aihua Zhao Miao Xu |
| author_sort | Junli Li |
| collection | DOAJ |
| description | Since 2019, there has been a growing focus on mRNA vaccines for infectious disease prevention, particularly following the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). mRNA vaccines offer advantages such as rapid production and the ability to induce robust cellular and antibody responses, which are essential for combating infections that require cell-mediated immunity, including Tuberculosis (TB). This review explores recent progress in TB mRNA vaccines and addresses several key areas: (1) the urgent need for new TB vaccines; (2) current advancements in TB vaccine development, and the advantages and challenges of mRNA technology; (3) the design and characteristics of TB mRNA vaccines; (4) the immunological mechanisms of TB mRNA vaccines; (5) manufacturing processes for TB mRNA vaccines; and (6) safety and regulatory considerations. This interdisciplinary review aims to provide insights for researchers working to address critical questions in TB mRNA vaccine development. |
| format | Article |
| id | doaj-art-c69fa1aa274b4738a6a2b1b626eaf0cd |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-c69fa1aa274b4738a6a2b1b626eaf0cd2025-08-20T03:48:14ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2469333RNA vaccines: The dawn of a new age for tuberculosis?Junli Li0Dong Liu1Xiaochi Li2Jiazheng Wei3Weixin Du4Aihua Zhao5Miao Xu6Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, ChinaGraduate School of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, ChinaDivision of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, ChinaCollege of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, ChinaDivision of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, ChinaDivision of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, ChinaDivision of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing, ChinaSince 2019, there has been a growing focus on mRNA vaccines for infectious disease prevention, particularly following the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). mRNA vaccines offer advantages such as rapid production and the ability to induce robust cellular and antibody responses, which are essential for combating infections that require cell-mediated immunity, including Tuberculosis (TB). This review explores recent progress in TB mRNA vaccines and addresses several key areas: (1) the urgent need for new TB vaccines; (2) current advancements in TB vaccine development, and the advantages and challenges of mRNA technology; (3) the design and characteristics of TB mRNA vaccines; (4) the immunological mechanisms of TB mRNA vaccines; (5) manufacturing processes for TB mRNA vaccines; and (6) safety and regulatory considerations. This interdisciplinary review aims to provide insights for researchers working to address critical questions in TB mRNA vaccine development.https://www.tandfonline.com/doi/10.1080/21645515.2025.2469333TuberculosismRNA vaccinesMycobacterium tuberculosisimmunological mechanismsmanufacture and quality control |
| spellingShingle | Junli Li Dong Liu Xiaochi Li Jiazheng Wei Weixin Du Aihua Zhao Miao Xu RNA vaccines: The dawn of a new age for tuberculosis? Human Vaccines & Immunotherapeutics Tuberculosis mRNA vaccines Mycobacterium tuberculosis immunological mechanisms manufacture and quality control |
| title | RNA vaccines: The dawn of a new age for tuberculosis? |
| title_full | RNA vaccines: The dawn of a new age for tuberculosis? |
| title_fullStr | RNA vaccines: The dawn of a new age for tuberculosis? |
| title_full_unstemmed | RNA vaccines: The dawn of a new age for tuberculosis? |
| title_short | RNA vaccines: The dawn of a new age for tuberculosis? |
| title_sort | rna vaccines the dawn of a new age for tuberculosis |
| topic | Tuberculosis mRNA vaccines Mycobacterium tuberculosis immunological mechanisms manufacture and quality control |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2469333 |
| work_keys_str_mv | AT junlili rnavaccinesthedawnofanewagefortuberculosis AT dongliu rnavaccinesthedawnofanewagefortuberculosis AT xiaochili rnavaccinesthedawnofanewagefortuberculosis AT jiazhengwei rnavaccinesthedawnofanewagefortuberculosis AT weixindu rnavaccinesthedawnofanewagefortuberculosis AT aihuazhao rnavaccinesthedawnofanewagefortuberculosis AT miaoxu rnavaccinesthedawnofanewagefortuberculosis |